The Food and Drug Administration approved oral semaglutide 25 mg on December 22, 2025, clearing Novo Nordisk's Wegovy pill as the first glucagon-like peptide-1 receptor agonist indicated for chronic weight management and reduction of major adverse cardiovascular events in adults with obesity or overweight with at least one weight-related comorbidity. BioPharma Dive reported the approval as a Monday decision that added a once-daily tablet to a class previously available only as weekly subcutaneous injections for weight loss. Novo Nordisk began U.S. pharmacy distribution in early January 2026.
Within weeks, healthcare analytics firm Truveta documented thousands of patients entering GLP-1 therapy through the pill who had not previously used injectable versions. The firm's report pointed to "the potential for oral formulations to expand access beyond patients already receiving injectable therapies," and the volume of switchers from injectables indicated patient preference for the oral route is altering utilization patterns. BioSpace reported the Truveta findings alongside the observation that the pill drew a new wave of patients into the weight loss peptides category.
Trial data and the empty-stomach condition
Figure 1: Metabolic receptor signaling and cellular endocrine pathway for Oral Wegovy's Launch Reshapes the Peptide Hierarchy: Injection vs. Pill.
The approval rested on the 64-week Phase 3b OASIS 4 trial (NCT05564117), which enrolled 307 adults. Participants receiving once-daily oral semaglutide 25 mg alongside lifestyle counseling lost a mean 16.6% of body weight when adherent to treatment, a result Novo Nordisk characterized as comparable to the 2.4-mg injectable. One in three participants lost 20% or more of baseline weight. AJMC's approval coverage quoted Novo Nordisk CEO Mike Doustdar: "The pill is here. With today's approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection."
The tablet carries a daily administration constraint that distinguishes it from the weekly injection. Patients must take it on an empty stomach with a small amount of plain water, then wait roughly 30 minutes before eating, drinking, or taking other medications. The same restriction governed Rybelsus, Novo Nordisk's lower-dose oral semaglutide approved for type 2 diabetes in 2019, which physicians noted saw limited uptake partly because of those requirements. For the broader category of oral peptides, the absorption-enhancer strategy overcomes gastric degradation but imposes a behavioral cost that a once-weekly injection avoids.
On February 5, 2026, the FDA issued an untitled letter to Novo Nordisk flagging marketing materials that "misleadingly suggest that because of its dosage form (i.e., pill), Wegovy offers an advancement or improvement (i.e., superior efficacy)." The agency noted those claims had not been demonstrated in the approved prescribing information.
Payer budgets and the broadened eligible population
The pill did not ease the financial pressure GLP-1 therapies place on commercial and employer-sponsored insurance. AJMC's analysis of the oral GLP-1 era found that even before oral formulations entered the market, plans reported GLP-1s represented a disproportionate share of claims growth and pharmacy-budget expansion. The analysis noted that as oral options appeal to injection-averse patients, demand is "likely to broaden still further, potentially amplifying existing cost pressures in commercial and employer-sponsored benefits." Early pricing signals cited in the same report suggest oral formulations may be priced at levels comparable to their injectable counterparts, meaning the shift in delivery route does not alter the per-patient cost equation. Prior-authorization requirements and step-therapy edits built around injectable Wegovy and Zepbound remain in place.
The regulatory queue behind oral semaglutide
Eli Lilly's orforglipron, a once-daily oral GLP-1 receptor agonist that is not a peptide and requires no food or water restrictions, is currently under FDA review. The agency's approval coverage identified the submission as a direct competitive entry against oral semaglutide's first-mover position. Separately, Lilly's injectable triple agonist retatrutide, targeting GLP-1, GIP, and glucagon receptors simultaneously, produced average weight loss of 28.3% at 80 weeks and 30.3% at 104 weeks in the Phase 3 TRIUMPH-1 trial—figures that approach bariatric surgery outcomes and exceed any currently listed FDA-approved peptide for weight management.
Across the Atlantic, the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on May 21, 2026, recommending Wegovy tablets in four strengths (1.5 mg, 4 mg, 9 mg, and 25 mg) for the EU market. That variation would extend Novo Nordisk's oral franchise beyond U.S. distribution channels.
Retatrutide has not received FDA approval, and Lilly has not announced a regulatory submission timeline for the triple agonist. Orforglipron's review clock is running. The OASIS 4 trial enrolled 307 participants over 64 weeks; long-term adherence data beyond that window, performance in patients with gastrointestinal conditions that could impair absorption, and head-to-head comparisons against orforglipron have not been published.
